C Ryan Miller

List of Publications by Year
in descending order

117 papers	21,600 citations	38660 50 h-index	24179 110 g-index
120 all docs	120 docs citations	120 times ranked	26481 citing authors

#	Article	IF	Citations
1	Type 1 diabetes and oral health: Findings from the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Journal of Diabetes and Its Complications, 2022, 36, 108120.	1.2	8
2	PVT1 is a stress-responsive lncRNA that drives ovarian cancer metastasis and chemoresistance. Life Science Alliance, 2022, 5, e202201370.	1.3	7
3	Immunohistochemical evaluation of immune cell infiltration in canine gliomas. Veterinary Pathology, 2021, 58, 952-963.	0.8	13
4	Inhibition of Colony-Stimulating Factor-1 Receptor Enhances the Efficacy of Radiotherapy and Reduces Immune Suppression in Glioblastoma. In Vivo, 2021, 35, 119-129.	0.6	24
5	Generation and Profiling of Tumor-Homing Induced Neural Stem Cells from the Skin of Cancer Patients. Molecular Therapy, 2020, 28, 1614-1627.	3.7	10
6	Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics. Neuro-Oncology, 2020, 22, 1713-1714.	0.6	0
7	Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme. Journal of Controlled Release, 2020, 324, 1-16.	4.8	7
8	Comparative Molecular Life History of Spontaneous Canine and Human Gliomas. Cancer Cell, 2020, 37, 243-257.e7.	7.7	59
9	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. Neuro-Oncology, 2019, 21, 837-853.	0.6	66
10	IL-11 Induces Encephalitogenic Th17 Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2019, 203, 1142-1150.	0.4	26
11	Canine Primary Intracranial Cancer: A Clinicopathologic and Comparative Review of Glioma, Meningioma, and Choroid Plexus Tumors. Frontiers in Oncology, 2019, 9, 1151.	1.3	63
12	Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma. Clinical Cancer Research, 2018, 24, 3632-3643.	3.2	49
13	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro-Oncology, 2018, 20, 546-556.	0.6	93
14	Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection. Molecular Pharmaceutics, 2018, 15, 1309-1318.	2.3	38
15	Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma. Scientific Reports, 2018, 8, 1180.	1.6	22
16	Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Research, 2018, 20, 12.	2.2	27
17	Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nature Communications, 2018, 9, 1057.	5.8	66
18	MerTK as a therapeutic target in glioblastoma. Neuro-Oncology, 2018, 20, 92-102.	0.6	62

#	Article	IF	Citations
19	A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1039-1054.	0.9	105
20	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Research and Treatment, 2018, 171, 637-648.	1.1	40
21	Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection. PLoS ONE, 2018, 13, e0198596.	1.1	9
22	PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition. PLoS ONE, 2018, 13, e0200014.	1.1	18
23	Intrinsic Astrocyte Heterogeneity Influences Tumor Growth in Glioma Mouse Models. Brain Pathology, 2017, 27, 36-50.	2.1	28
24	Tumor-homing cytotoxic human induced neural stem cells for cancer therapy. Science Translational Medicine, 2017, 9, .	5.8	71
25	Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma. Neuro-Oncology, 2017, 19, 1237-1247.	0.6	16
26	Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro-Oncology, 2017, 19, 1481-1493.	0.6	32
27	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Science Translational Medicine, 2017, 9, .	5.8	89
28	Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro-Oncology, 2017, 19, 1469-1480.	0.6	42
29	Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer. Nanomedicine, 2017, 12, 2519-2532.	1.7	14
30	Putting â€œmultiformeâ€•back into glioblastoma: intratumoral transcriptome heterogeneity is a consequence of its complex morphology. Neuro-Oncology, 2017, 19, 1570-1571.	0.6	2
31	Cthrc1 lowers pulmonary collagen associated with bleomycinâ€•induced fibrosis and protects lung function. Physiological Reports, 2017, 5, e13115.	0.7	20
32	Ki-67 Expression in Breast Cancer Tissue Microarrays. American Journal of Clinical Pathology, 2017, 148, 108-118.	0.4	10
33	Pineal Region Glioblastoma, a Case Report and Literature Review. Frontiers in Oncology, 2017, 7, 123.	1.3	18
34	Paired Expression Analysis of Tumor Cell Surface Antigens. Frontiers in Oncology, 2017, 7, 173.	1.3	16
35	TMOD-01. FUNCTIONAL KINOME CHARACTERIZATION OF AÂDIVERSE PANEL OF GLIOBLASTOMA MODELS. Neuro-Oncology, 2016, 18, vi206-vi207.	0.6	1
36	TMOD-34. REACTIVE ASTROCYTES POTENTIATE TUMOR AGGRESSIVENESS IN AÂMURINE GLIOMA RESECTION AND RECURRENCE MODEL. Neuro-Oncology, 2016, 18, vi214-vi214.	0.6	1

#	Article	IF	Citations
37	Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. Neuro-Oncology, 2016, 18, 1209-1218.	0.6	75
38	BRAF Mutations Open Doors for N-Ethyl-N-Nitrosourea–Induced Gliomagenesis. American Journal of Pathology, 2016, 186, 2551-2554.	1.9	2
39	Hematopoietic Stem cell transplantation and lentiviral vector–based gene therapy for Krabbe's disease: Present convictions and future prospects. Journal of Neuroscience Research, 2016, 94, 1152-1168.	1.3	18
40	Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model. Neuro-Oncology, 2016, 18, 1622-1633.	0.6	92
41	Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 470-478.	1.1	53
42	Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma. Nature Communications, 2016, 7, 10593.	5.8	99
43	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 2016, 164, 550-563.	13.5	1,695
44	Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. Neuro-Oncology, 2016, 18, 962-973.	0.6	38
45	Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of *BRCA*-Mutated and *BRCA*–Wild-Type Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2015, 14, 920-930.	1.9	62
46	ASC deficiency suppresses proliferation and prevents medulloblastoma incidence. Oncogene, 2015, 34, 394-402.	2.6	9
47	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	13.9	2,582
48	IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma. Clinical Cancer Research, 2015, 21, 2167-2176.	3.2	16
49	Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis. Neuro-Oncology, 2015, 17, 1220-1230.	0.6	33
50	Contemporary murine models in preclinical astrocytoma drug development. Neuro-Oncology, 2015, 17, 12-28.	0.6	23
51	Abstract 2579: Combination therapy with MEK inhibition is efficacious in intracranial triple negative breast cancer models. , 2015, , .		1
52	Modeling Astrocytoma Pathogenesis *In Vitro* and *In Vivo* Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice. Journal of Visualized Experiments, 2014, , e51763.	0.2	9
53	NT-38 * MerTK AS A TARGET IN GLIOBLASTOMA. Neuro-Oncology, 2014, 16, v166-v167.	0.6	0
54	Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models. Clinical Cancer Research, 2014, 20, 6083-6095.	3.2	89

#	Article	IF	Citations
55	Development of DNA Damage Response Signaling Biomarkers using Automated, Quantitative Image Analysis. Journal of Histochemistry and Cytochemistry, 2014, 62, 185-196.	1.3	14
56	ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma. European Urology, 2014, 66, 77-84.	0.9	234
57	Î±B-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain. Clinical Cancer Research, 2014, 20, 56-67.	3.2	87
58	Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4214-23.	3.3	105
59	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop. Neuro-Oncology, 2014, 16, 173-178.	0.6	23
60	Abstract 5449A: PI3K and MEK inhibition in intracranial triple negative breast cancer: Efficacy of BKM120 and AZD6244 in preclinical mouse models. , 2014, , .		1
61	Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. Journal of Clinical Investigation, 2014, 124, 553-563.	3.9	53
62	Cerebellar granule neuron progenitors are the source of Hk2 in the postnatal cerebellum. Cancer & Metabolism, 2013, 1, 15.	2.4	10
63	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
64	Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class. Clinical Cancer Research, 2013, 19, 4951-4960.	3.2	182
65	Validation of Interobserver Agreement in Lung Cancer Assessment: Hematoxylin-Eosin Diagnostic Reproducibility for Nonâ€"Small Cell Lung Cancer: The 2004 World Health Organization Classification and Therapeutically Relevant Subsets. Archives of Pathology and Laboratory Medicine, 2013, 137, 32-40.	1.2	54
66	Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE Specimens. Journal of Molecular Diagnostics, 2013, 15, 485-497.	1.2	16
67	Hexokinase-2-mediated aerobic glycolysis is integral to cerebellar neurogenesis and pathogenesis of medulloblastoma. Cancer & Metabolism, 2013, 1, 2.	2.4	96
68	Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nature Communications, 2013, 4, 1449.	5.8	111
69	Bax deficiency prolongs cerebellar neurogenesis, accelerates medulloblastoma formation and paradoxically increases both malignancy and differentiation. Oncogene, 2013, 32, 2304-2314.	2.6	31
70	Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis. Neuro-Oncology, 2013, 15, 1317-1329.	0.6	55
71	The Role of Ect2 Nuclear RhoGEF Activity in Ovarian Cancer Cell Transformation. Genes and Cancer, 2013, 4, 460-475.	0.6	51
72	Evolutionary etiology of high-grade astrocytomas. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17933-17938.	3.3	35

#	Article	IF	Citations
73	Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer. PLoS ONE, 2013, 8, e61359.	1.1	77
74	Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System. Brain Pathology, 2013, 23, 584-594.	2.1	53
75	Glioblastoma Multiforme: Relationship to Subventricular Zone and Recurrence. Neuroradiology Journal, 2013, 26, 542-547.	0.6	18
76	MERTK receptor tyrosine kinase is a therapeutic target in melanoma. Journal of Clinical Investigation, 2013, 123, 2257-2267.	3.9	124
77	HIF1Î± and HIF2Î± independently activate SRC to promote melanoma metastases. Journal of Clinical Investigation, 2013, 123, 2078-2093.	3.9	132
78	Diagnostic Utility of Major Basic Protein, Eotaxin-3, and Leukotriene Enzyme Staining in Eosinophilic Esophagitis. American Journal of Gastroenterology, 2012, 107, 1503-1511.	0.2	80
79	Genetically engineered mouse models of diffuse gliomas. Brain Research Bulletin, 2012, 88, 72-79.	1.4	22
80	An Animal Model of MYC-Driven Medulloblastoma. Cancer Cell, 2012, 21, 155-167.	7.7	267
81	LKB1/STK11 Inactivation Leads to Expansion of a Prometastatic Tumor Subpopulation in Melanoma. Cancer Cell, 2012, 21, 751-764.	7.7	116
82	Markers of tyrosine kinase activity in eosinophilic esophagitis: a pilot study of the FIP1L1-PDGFRÎ± fusion gene, pERK 1/2, and pSTAT5. Ecological Management and Restoration, 2012, 25, 166-174.	0.2	5
83	Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation. PLoS ONE, 2012, 7, e36530.	1.1	225
84	RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small GTPases, 2011, 2, 202-210.	0.7	32
85	Tryptase Staining of Mast Cells May Differentiate Eosinophilic Esophagitis from Gastroesophageal Reflux Disease. American Journal of Gastroenterology, 2011, 106, 264-271.	0.2	101
86	Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Research, 2011, 13, R125.	2.2	87
87	Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. British Journal of Cancer, 2011, 104, 545-553.	2.9	89
88	Gone FISHing: Clinical Lessons Learned in Brain Tumor Molecular Diagnostics over the Last Decade. Brain Pathology, 2011, 21, 57-73.	2.1	93
89	The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer, 2011, 117, 1602-1611.	2.0	125
90	High XRCC1 Protein Expression Is Associated with Poorer Survival in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2011, 17, 6542-6552.	3.2	49

#	Article	IF	Citations
91	Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010, 17, 98-110.	7.7	6,138
92	Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types. Clinical Cancer Research, 2010, 16, 4864-4875.	3.2	259
93	Malignant Gliomas with Primitive Neuroectodermal Tumorâ€like Components: A Clinicopathologic and Genetic Study of 53 Cases. Brain Pathology, 2009, 19, 81-90.	2.1	154
94	Risk of Recurrence of Resected Stage I Non-small Cell Lung Cancer in Elderly Patients as Compared with Younger Patients. Journal of Thoracic Oncology, 2009, 4, 1370-1374.	0.5	58
95	Modeling Astrocytomas in a Family of Inducible Genetically Engineered Mice: Implications for Preclinical Cancer Drug Development. , 2009, , 119-145.		1
96	Cancer gene therapy. , 2009, , 589-612.		2
97	Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. Pharmacogenomics, 2008, 9, 1459-1466.	0.6	24
98	A Clinical Model to Estimate Recurrence Risk in Resected Stage I Non-Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 22-28.	0.6	31
99	Gray Zones in Brain Tumor Classification. Advances in Anatomic Pathology, 2008, 15, 287-297.	2.4	38
100	PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncology Reports, 2007, 17, 853.	1.2	26
101	Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene, 2007, 26, 2563-2573.	2.6	156
102	Glioblastoma. Archives of Pathology and Laboratory Medicine, 2007, 131, 397-406.	1.2	174
103	Clinical significance of prospective molecular genetic analysis of glial neoplasms: The Washington University FISH Laboratory experience. FASEB Journal, 2007, 21, A26.	0.2	0
104	Pharmacogenomics of cancer chemotherapy-induced toxicity. The Journal of Supportive Oncology, 2007, 5, 9-14.	2.3	14
105	Multifocal Langerhans cell histiocytosis of the pediatric spine: a case report and literature review. Child's Nervous System, 2006, 23, 127-131.	0.6	19
106	Significance of Necrosis in Grading of Oligodendroglial Neoplasms: A Clinicopathologic and Genetic Study of Newly Diagnosed High-Grade Gliomas. Journal of Clinical Oncology, 2006, 24, 5419-5426.	0.8	158
107	Î"24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Therapy, 2005, 12, 284-294.	2.2	62
108	Cancer gene therapy. , 2003, , 583-613.		1

#	Article	IF	Citations
109	Quantitation of Cytosine Deaminase mRNA by Real-Time Reverse Transcription Polymerase Chain Reaction: A Sensitive Method for Assessing 5-Fluorocytosine Toxicity in Vitro. Analytical Biochemistry, 2002, 301, 189-199.	1.1	5
110	Application of Molecular Biology Studies to Gene Therapy Treatment Strategies. World Journal of Surgery, 2002, 26, 854-860.	0.8	7
111	Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Research, 2002, 62, 773-80.	0.4	91
112	Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Molecular Cancer Therapeutics, 2002, 1, 1139-45.	1.9	29
113	A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nature Biotechnology, 1999, 17, 470-475.	9.4	132
114	Retargeting to EGFR Enhances Adenovirus Infection Efficiency of Squamous Cell Carcinoma. JAMA Otolaryngology, 1999, 125, 856.	1.5	65
115	An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism. Journal of Virology, 1998, 72, 9706-9713.	1.5	713
116	Characterization of an Adenovirus Vector Containing a Heterologous Peptide Epitope in the HI Loop of the Fiber Knob. Journal of Virology, 1998, 72, 1844-1852.	1.5	296
117	Development of Monoclonal Antibodies to the Malondialdehydeâˆ'Deoxyguanosine Adduct, Pyrimidopurinone1. Chemical Research in Toxicology, 1997, 10, 172-180.	1.7	44